BR0315866A - Conjugados lìquidos de produtos farmacêuticos sólidos - Google Patents

Conjugados lìquidos de produtos farmacêuticos sólidos

Info

Publication number
BR0315866A
BR0315866A BR0315866-7A BR0315866A BR0315866A BR 0315866 A BR0315866 A BR 0315866A BR 0315866 A BR0315866 A BR 0315866A BR 0315866 A BR0315866 A BR 0315866A
Authority
BR
Brazil
Prior art keywords
liquid
solid pharmaceuticals
conjugates
liquid conjugates
solid
Prior art date
Application number
BR0315866-7A
Other languages
English (en)
Inventor
Shalaby Wahba Shalaby
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Poly Med Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Poly Med Inc filed Critical Pfizer Prod Inc
Publication of BR0315866A publication Critical patent/BR0315866A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"CONJUGADOS LìQUIDOS DE PRODUTOS FARMACêUTICOS SóLIDOS". A presente invenção refere-se a um conjugado de fase líquida formado de um agente bioativo tal como um composto de droga, por exemplo ziprasidona, e um polímero liquido com a funcionalidade requerida.
BR0315866-7A 2002-10-31 2003-10-24 Conjugados lìquidos de produtos farmacêuticos sólidos BR0315866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42283302P 2002-10-31 2002-10-31
PCT/IB2003/004698 WO2004039410A2 (en) 2002-10-31 2003-10-24 Liquid conjugates of solid pharmaceuticals

Publications (1)

Publication Number Publication Date
BR0315866A true BR0315866A (pt) 2005-09-27

Family

ID=32230393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315866-7A BR0315866A (pt) 2002-10-31 2003-10-24 Conjugados lìquidos de produtos farmacêuticos sólidos

Country Status (8)

Country Link
US (1) US20040147532A1 (pt)
EP (1) EP1556087A2 (pt)
JP (1) JP2006506396A (pt)
AU (1) AU2003274419A1 (pt)
BR (1) BR0315866A (pt)
CA (1) CA2504345A1 (pt)
MX (1) MXPA05003659A (pt)
WO (1) WO2004039410A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
WO2015165976A1 (en) 2014-05-01 2015-11-05 Ingell Technologies Holding B.V. Liquid triblock copolymer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
HUT62465A (en) 1990-05-01 1993-05-28 Res Triangle Inst Biologically degredable reservoir ensuring delayed release of medicine
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
JP3220331B2 (ja) * 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
US5612052A (en) * 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5665702A (en) * 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
TW305092B (en) * 1996-03-04 1997-05-11 Multiplex Technology Inc Apparatus and method for transmitting electrical power and broadband RF communications signals through a dielectric
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
JP4656725B2 (ja) 1997-10-03 2011-03-23 プロセリックス・ソルト・レイク・シティ，インコーポレーテッド 逆熱的ゲル化特性を有する生分解性低分子量トリブロックポリ（ラクチド−ｃｏ−グリコリド）−ポリエチレングリコールコポリマー
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6469132B1 (en) * 1999-05-05 2002-10-22 Mcgill University Diblock copolymer and use thereof in a micellar drug delivery system
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US7119246B2 (en) * 2002-06-25 2006-10-10 Perry Robins Method of treating acne

Also Published As

Publication number Publication date
MXPA05003659A (es) 2005-09-20
CA2504345A1 (en) 2004-05-13
AU2003274419A1 (en) 2004-05-25
EP1556087A2 (en) 2005-07-27
WO2004039410A2 (en) 2004-05-13
AU2003274419A8 (en) 2004-05-25
US20040147532A1 (en) 2004-07-29
WO2004039410A3 (en) 2004-07-22
JP2006506396A (ja) 2006-02-23

Similar Documents

Publication Publication Date Title
DE60025482D1 (de) Spritzgegossener stopfen für arzneimittelbehälter
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
ATE368066T1 (de) Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
BR0208338A (pt) Derivados de piridina
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
BR0210139A (pt) Composições farmacêuticas
ATE536163T1 (de) Verpackung für medizinische produkte und dergleichen
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
EE200200522A (et) Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina
PL337499A1 (en) Novel 2-(iminomethyl)aminophenylic derivatives, their production and application as drugs and pharmaceutic agents containing such derivatives
BR0317682A (pt) Composição farmacêutica de liberação modificada
WO2007005941A3 (en) Liver targeted conjugates
BR0211601A (pt) Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
NO20064783L (no) Opplosningstabeletter med licarbazepin
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
IT1308678B1 (it) Siringa per infusione di farmaci.
BR0315866A (pt) Conjugados lìquidos de produtos farmacêuticos sólidos
ES2147163A1 (es) Una composicion farmaceutica con actividad reguladora de la expresion de las moleculas de adhesion.
BR0315895A (pt) Conjugados iÈnicos poliméricos sólidos e semi-sólidos, composição farmacêutica, processo para preparação dos referidos conjugados e composição sólida ou semi-sólida
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/59 (2017.01), A61K 47/60 (2017.01)